中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.017 seconds)

    FLUORESCENCE DETECTION APPARATUS, ANALYSIS METHOD, AND FLUORESCENCE DETECTION SYSTEM
    1.
    发明申请
    FLUORESCENCE DETECTION APPARATUS, ANALYSIS METHOD, AND FLUORESCENCE DETECTION SYSTEM 审中-公开

    公开(公告)号：US20190056323A1

    公开(公告)日：2019-02-21

    申请号：US15770593

    申请日：2016-11-04

    Applicant: SHISEIDO COMPANY, LTD. ,  KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

    Inventor： Masashi MITA ,  Eiichi NEGISHI ,  Kazuhiko Mibayashi ,  Kenji HAMASE

    IPC: G01N21/64 ,  G01N30/74 ,  G01N33/50 ,  G01N30/46

    Abstract: [Problem]To provide a fluorescence detection apparatus that is capable of simultaneously detecting a plurality of analyte components contained at different concentrations with a wide measurement range.[Solution]A fluorescence detection apparatus 100 includes a cell 110 into which an analyte of a sample is introduced, a light source 130 that irradiates excitation light on the analyte in the cell; a first detector 52 that detects fluorescence generated from the analyte after the excitation light has been irradiated on the analyte, and a second detector 53 that detects the fluorescence generated from the analyte after the excitation light has been irradiated on the analyte. The second detector detects the fluorescence with a measurement range that is different from the measurement range of the first detector, and the first detector and second detector detect the fluorescence simultaneously.

    MARKER FOR EARLY DIAGNOSIS OF KIDNEY FAILURE
    3.
    发明申请
    MARKER FOR EARLY DIAGNOSIS OF KIDNEY FAILURE 审中-公开

    公开(公告)号：US20190339282A1

    公开(公告)日：2019-11-07

    申请号：US16511097

    申请日：2019-07-15

    Applicant: Shiseido Company, Ltd.

    Inventor： Kenji Hamase ,  Yurika MIYOSHI ,  Masashi MITA

    IPC: G01N33/68

    Abstract: The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

    METHOD FOR PRETREATMENT AND METHOD FOR ANALYSIS OF LENALIDOMIDE IN BIOLOGICAL SAMPLE
    5.
    发明申请
    METHOD FOR PRETREATMENT AND METHOD FOR ANALYSIS OF LENALIDOMIDE IN BIOLOGICAL SAMPLE 审中-公开

    公开(公告)号：US20170192024A1

    公开(公告)日：2017-07-06

    申请号：US15312777

    申请日：2015-05-21

    Applicant: Shiseido Company, Ltd

    Inventor： Yosuke TOJO ,  Masashi MITA ,  Wolfgang Lindner

    IPC: G01N33/94 ,  B01D15/12 ,  B01D15/26 ,  B01D15/16

    Abstract: The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.

    MARKER FOR EARLY DIAGNOSIS OF KIDNEY FAILURE
    6.
    发明申请
    MARKER FOR EARLY DIAGNOSIS OF KIDNEY FAILURE 审中-公开

    公开(公告)号：US20190339281A1

    公开(公告)日：2019-11-07

    申请号：US16231381

    申请日：2018-12-21

    Applicant: Shiseido Company, Ltd.

    Inventor： Kenji HAMASE ,  Yurika MIYOSHI ,  Masashi MITA

    IPC: G01N33/68

    Abstract: The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

    METHOD FOR QUANTITATIVELY ANALYZING CYSTEINE AND CYSTINE AND REAGENT KIT FOR QUANTITATIVELY ANALYZING CYSTEINE AND CYSTINE
    7.
    发明申请
    METHOD FOR QUANTITATIVELY ANALYZING CYSTEINE AND CYSTINE AND REAGENT KIT FOR QUANTITATIVELY ANALYZING CYSTEINE AND CYSTINE 有权
    用于定量分析CYSTEINE和CYSTINE和试剂盒的定量分析CYSTEINE和CYSTINE的方法

    公开(公告)号：US20150064797A1

    公开(公告)日：2015-03-05

    申请号：US14472982

    申请日：2014-08-29

    Applicant: SHISEIDO COMPANY, LTD. ,  KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

    Inventor： Masashi MITA ,  Kenji HAMASE

    IPC: G01N31/00

    CPC classification number: G01N31/005 ,  G01N33/6815 ,  Y10T436/182

    Abstract: A method for quantitatively analyzing cysteine and cysteine includes a first step of adding a methyl-sulfurating agent to a sample that includes cysteine and cystine to obtain a methyl-sulfurated cysteine, a second step of adding a derivatizing agent to the methyl-sulfurated cysteine and the cystine to obtain a cysteine derivative and a cystine derivative, respectively, and a third step of quantifying the cysteine derivative and the cystine derivative.

    Abstract translation: 用于定量分析半胱氨酸和半胱氨酸的方法包括向包含半胱氨酸和胱氨酸的样品中加入甲基硫化剂以获得甲基 - 硫化半胱氨酸的第一步骤，向甲基 - 硫化半胱氨酸添加衍生化试剂的第二步骤和 分别得到半胱氨酸衍生物和胱氨酸衍生物的胱氨酸，第三步是定量半胱氨酸衍生物和胱氨酸衍生物。

    MARKER FOR EARLY DIAGNOSIS OF KIDNEY FAILURE
    9.
    发明申请
    MARKER FOR EARLY DIAGNOSIS OF KIDNEY FAILURE 审中-公开
    早期诊断KIDNEY失败的标记

    公开(公告)号：US20160313342A1

    公开(公告)日：2016-10-27

    申请号：US15103539

    申请日：2014-12-11

    Applicant: SHISEIDO COMPANY, LTD. ,  KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

    Inventor： Kenji Hamase ,  Yurika MIYOSHI ,  Masashi MITA

    IPC: G01N33/68

    CPC classification number: G01N33/6812 ,  G01N2800/347

    Abstract: The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

    Abstract translation: 本发明解决了鉴定肾衰竭的生物标志物的问题，所述生物标志物可从尿液或血液中获得，并且从早期阶段比肾小球滤过率和血清肌酐水平波动，从而开发用于诊断早期肾衰竭的技术。 用于分析肾衰竭疑似受试者的血液，血浆，血清或尿液的方法包括测量一对D型和L型的至少一种氨基酸的浓度的步骤，所述氨基酸选自由以下组成的氨基酸组： [D-丝氨酸]和[L-丝氨酸]等，包含在受试者的血液，血浆，血清或尿液中，并计算作为受试者的病理学指标，D型浓度与 L型浓度或D-型浓度相对于D-型和L-型总浓度的百分比。

Patent Agency Ranking